The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform
Timo Seppälä - One of the best experts on this subject based on the ideXlab platform.
-
Steroid Use and Long-Term Health Risks in Former Athletes
Sports Medicine, 2002Co-Authors: Miia Pärssinen, Timo SeppäläAbstract:This article focuses on Anabolic steroid adverse effects on the cardiovascular system and mental health issues as well as the possible increase in the incidence of neoplasms in Anabolic steroid users. On the basis of findings in the literature, the authors consider these three issues as the most significant concerning morbidity and mortality among Anabolic steroid users. A study by Pärssinen et al. (2000) has shown an increased incidence of premature mortality among power lifters. Anabolic steroids and other concomitantly used drugs are the probable cause of this increased mortality, as power training itself does not increase health risks and all types of physical activity promote health.
John Paul Wright - One of the best experts on this subject based on the ideXlab platform.
-
Anabolic androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the united states
American Journal of Public Health, 2008Co-Authors: Kevin M Beaver, Michael G Vaughn, Matt Delisi, John Paul WrightAbstract:We examined the effects of Anabolic-androgenic steroid use on serious violent behavior. Multivariate models based on data from the National Longitudinal Study of Adolescent Health (N = 6823) were used to examine the association between lifetime and past-year self-reported Anabolic-androgenic steroid use and involvement in violent acts. Compared with individuals who did not use steroids, young adult males who used Anabolic-androgenic steroids reported greater involvement in violent behaviors after we controlled for the effects of key demographic variables, previous violent behavior, and polydrug use.
John P. Bilezikian - One of the best experts on this subject based on the ideXlab platform.
-
Combination Anabolic and antiresorptive therapy for osteoporosis: opening the Anabolic window.
Current Osteoporosis Reports, 2008Co-Authors: John P. BilezikianAbstract:Antiresorptive agents for osteoporosis are a cornerstone of therapy, but Anabolic drugs have recently increased our options. By stimulating bone formation, Anabolic agents reduce fracture incidence by improving bone qualities in addition to increasing bone mass. The only Anabolic agent currently approved for osteoporosis by the US Food and Drug Administration, teriparatide (recombinant human parathyroid hormone [1–34]), has emerged as a major approach to selected patients with osteoporosis. Recombinant human parathyroid hormone (1–84) is also available in Europe. Teriparatide increases bone density and bone turnover, improves microarchitecture, and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. A current concept in the mechanism of teriparatide action is related to its effect to stimulate processes associated with bone formation before it stimulates processes associated with bone resorption. This sequence of events has led to the concept of the Anabolic window, the period of time when teriparatide is maximally Anabolic. Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents have led to ways in which the Anabolic window can be expanded.
-
Anabolic therapy for osteoporosis.
Women's Health, 2007Co-Authors: John P. BilezikianAbstract:Antiresorptive agents for osteoporosis are a cornerstone of therapy, but Anabolic drugs have recently increased our options. By directly stimulating bone formation, Anabolic agents reduce fracture incidence by improving bone qualities as well as increasing bone mass. The Anabolic agent currently approved for osteoporosis, teriparatide (recombinant human parathyroid hormone[1-34]), has emerged as a major approach for selected patients with osteoporosis. Parathyroid hormone(1-84) is also available in Europe. Teriparatide increases bone density and bone turnover, improves microarchitecture and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. A current concept in the mechanism of teriparatide action is related to its effect of stimulating processes associated with bone formation before processes associated with bone resorption. This sequence of events has led to the concept of the Anabolic window, the period of time when teriparatide is maximally Anabolic. Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents has led to ways in which the Anabolic window can be expanded.
-
Anabolic skeletal therapy for osteoporosis
Arquivos Brasileiros De Endocrinologia E Metabologia, 2006Co-Authors: Monica Girotra, Mishaela R. Rubin, John P. BilezikianAbstract:Antiresorptive agents for osteoporosis are a cornerstone of therapy, but Anabolic drugs have recently widened our therapeutic options. By directly stimulating bone formation, Anabolic agents reduce fracture incidence by improving bone qualities besides increasing bone mass. In this article, we review the role of Anabolic treatment for osteoporosis. The only Anabolic agent currently approved in the United States for osteoporosis, teriparatide [recombinant human parathyroid hormone(1-34)], has clearly emerged as a major approach to selected patients with osteoporosis. Teriparatide increases bone density and bone turnover, improves microarchitecture, and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. Teriparatide is approved for both postmenopausal women and men with osteoporosis who are at high risk for fracture. Other potential Anabolic therapies for osteoporosis, including other forms of parathyroid hormone, strontium ranelate, growth hormone, and insulin-like growth factor-1, are also reviewed in this article.
-
New Anabolic therapies in osteoporosis
Endocrinology and Metabolism Clinics of North America, 2003Co-Authors: Mishaela R. Rubin, John P. BilezikianAbstract:Anabolic agents represent an important new advance in the therapy of osteoporosis. Their potential might be substantially greater than the anti-resorptives. Because the anti-resorptives and Anabolic agents work by completely distinct mechanisms of action, it is possible that the combination of agents could be significantly more potent than either agent alone. Recent evidence suggests that a plateau in BMD might occur after prolonged exposure to PTH. Anti-resorptive therapy during or after Anabolic therapy might prevent this skeletal adaptation. Protocols to consider Anabolic agents as intermittent recycling therapy would be of interest. Of all the Anabolics, PTH is the most promising. However, there are unanswered questions about PTH. More studies are needed to document an Anabolic effect on cortical bone. More large-scale studies are needed to further determine the reduction in nonvertebral fractures with PTH, especially at the hip. In the future, PTH is likely to be modified for easier and more targeted delivery. Oral or transdermal delivery systems may become available. Recently, Gowen et al have described an oral calcilytic molecule that antagonizes the parathyroid cell calcium receptor, thus stimulating the endogenous release of PTH. This approach could represent a novel endogenous delivery system for intermittent PTH administration. Rising expectations that Anabolic therapies for osteoporosis will soon play a major role in treating this disease are likely to fuel further studies and the development of even more novel approaches to therapy.
-
New Anabolic therapies in osteoporosis.
Current Opinion in Rheumatology, 2002Co-Authors: Mishaela R. Rubin, John P. BilezikianAbstract:While antiresorptive drugs have been the cornerstone of osteoporosis therapy, Anabolic drugs are an important new advance in the treatment of osteoporosis. By directly stimulating bone formation, Anabolic agents might have greater potential than the antiresorptives to increase bone mass and to decrease fractures. It is also possible that the combination of an antiresorptive agent with an Anabolic agent could be more potent than either agent alone. Potential Anabolic therapies for osteoporosis, including fluoride, growth hormone, insulin-like growth factor-I, strontium, and parathyroid hormone, are reviewed here. Of these, parathyroid hormone has clearly emerged as the most promising treatment at this time.
Miia Pärssinen - One of the best experts on this subject based on the ideXlab platform.
-
Steroid Use and Long-Term Health Risks in Former Athletes
Sports Medicine, 2002Co-Authors: Miia Pärssinen, Timo SeppäläAbstract:This article focuses on Anabolic steroid adverse effects on the cardiovascular system and mental health issues as well as the possible increase in the incidence of neoplasms in Anabolic steroid users. On the basis of findings in the literature, the authors consider these three issues as the most significant concerning morbidity and mortality among Anabolic steroid users. A study by Pärssinen et al. (2000) has shown an increased incidence of premature mortality among power lifters. Anabolic steroids and other concomitantly used drugs are the probable cause of this increased mortality, as power training itself does not increase health risks and all types of physical activity promote health.
A H Young - One of the best experts on this subject based on the ideXlab platform.
-
psychiatric effects of androgenic and Anabolic androgenic steroid abuse in men a brief review of the literature
Journal of Psychopharmacology, 1992Co-Authors: D J Williamson, A H YoungAbstract:Drug abuse is common in sport and many athletes take large doses of Anabolic-androgenic steroids. It has been suspected for some time that these drugs may have psychological effects. In the past, attempts have been made to demonstrate beneficial psychotropic effects. Recent literature suggests a high incidence of psychiatric morbidity in Anabolic-androgenic steroid abusers. In addition, some Anabolic-androgenic steroid abusers have been noted to exhibit addictive behaviour. Further study of this unique group who self-administer massive doses of synthetic male hormones is warranted.
